KR20140139563A - 캡슐화된 디에틸렌트리아민펜타아세테이트 입자들의 경구 전달을 위한 조성물 및 방법 - Google Patents

캡슐화된 디에틸렌트리아민펜타아세테이트 입자들의 경구 전달을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20140139563A
KR20140139563A KR1020147028955A KR20147028955A KR20140139563A KR 20140139563 A KR20140139563 A KR 20140139563A KR 1020147028955 A KR1020147028955 A KR 1020147028955A KR 20147028955 A KR20147028955 A KR 20147028955A KR 20140139563 A KR20140139563 A KR 20140139563A
Authority
KR
South Korea
Prior art keywords
dtpa
composition
particles
less
average diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147028955A
Other languages
English (en)
Korean (ko)
Inventor
제임스 데이비드 탈톤
Original Assignee
나노테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나노테라퓨틱스, 인코포레이티드 filed Critical 나노테라퓨틱스, 인코포레이티드
Publication of KR20140139563A publication Critical patent/KR20140139563A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147028955A 2012-03-22 2013-03-14 캡슐화된 디에틸렌트리아민펜타아세테이트 입자들의 경구 전달을 위한 조성물 및 방법 Ceased KR20140139563A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261614333P 2012-03-22 2012-03-22
US61/614,333 2012-03-22
US201361771873P 2013-03-03 2013-03-03
US61/771,873 2013-03-03
PCT/US2013/031336 WO2013142258A1 (en) 2012-03-22 2013-03-14 Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles

Publications (1)

Publication Number Publication Date
KR20140139563A true KR20140139563A (ko) 2014-12-05

Family

ID=48014341

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147028955A Ceased KR20140139563A (ko) 2012-03-22 2013-03-14 캡슐화된 디에틸렌트리아민펜타아세테이트 입자들의 경구 전달을 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US9040091B2 (enExample)
EP (1) EP2827853A1 (enExample)
JP (1) JP2015510935A (enExample)
KR (1) KR20140139563A (enExample)
AU (1) AU2013235491A1 (enExample)
CA (1) CA2867701C (enExample)
MX (1) MX2014011123A (enExample)
WO (1) WO2013142258A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160135204A (ko) * 2014-02-18 2016-11-25 메데시스 파마 방사성 핵종 및 금속의 킬레이트제를 전달하기 위한 역-미셀계의 이용

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
JP2018052884A (ja) * 2016-09-29 2018-04-05 菊川　正 放射線核種キレート化剤を内包する経口投与剤
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
KR20260020183A (ko) 2023-06-05 2026-02-10 나노파마슈틱스, 인크. 서방성 결정질 prx-3140의 경구 전달을 위한 조성물 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
UA76810C2 (uk) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
US7910086B1 (en) * 2005-01-04 2011-03-22 Gp Medical, Inc. Nanoparticles for protein drug delivery
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
US7914767B2 (en) * 2006-02-17 2011-03-29 Sri International Oral DTPA for radionuclide chelation
KR20130100897A (ko) * 2010-04-21 2013-09-12 나노메가 메디컬 코포레이션 나노입자의 약제학적 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160135204A (ko) * 2014-02-18 2016-11-25 메데시스 파마 방사성 핵종 및 금속의 킬레이트제를 전달하기 위한 역-미셀계의 이용

Also Published As

Publication number Publication date
JP2015510935A (ja) 2015-04-13
US9040091B2 (en) 2015-05-26
CA2867701C (en) 2020-10-27
US20130251815A1 (en) 2013-09-26
CA2867701A1 (en) 2013-09-26
MX2014011123A (es) 2014-12-05
WO2013142258A1 (en) 2013-09-26
EP2827853A1 (en) 2015-01-28
AU2013235491A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
JP5748732B2 (ja) ガナキソロン製剤、およびその作製方法、およびその使用
AU2007260822B2 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP3131541A1 (en) Ion channel activators and methods of use
JP2002522474A (ja) ナノ粒状ナプロキセンの注射可能製剤
US9040091B2 (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
CN101484170A (zh) 包含纳米颗粒萘普生和控释氢可酮的组合物
MX2011002847A (es) Polvo de compuesto organico combinado para uso medico y metodo de produccion y suspension del mismo.
JP6605047B2 (ja) 疼痛治療のためのセレコキシブの経口用組成物
US20210030693A1 (en) Pharmaceutical active-containing film delivery device for oral transmucosal administration
TW201113050A (en) 3-cyanoquinoline tablet formulations and uses thereof
US8741344B1 (en) Dispersible tablet
EP3970703B1 (en) Novel nanoparticles using anionic polymer, preparation method and composition thereof
CN110022901A (zh) 含有塞来昔布的药物组合物
AU2013347264B2 (en) Dispersible tablet
EP4561531A1 (en) A stable pharmaceutical oral liquid formulation of an antispasmodic agent
KR20240004942A (ko) 2,4,6-트리플루오로-n-[6-(1-메틸-피페리딘-4-카르보닐)-피리딘-2-일]-벤즈아미드헤미숙시네이트의 맛 차폐된 조성물 및 그를 포함하는 경구 붕해 정제
DK177906B1 (en) Dispersible tablet
US20150283083A1 (en) Dispersible Tablet
WO2025185023A1 (zh) 新藤黄酸脂肪体及其制备方法与应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)